The role of DNA synthesis imaging in cancer in the era of targeted therapeutics

Cancer and Metastasis Reviews

Volumn 27, Issue 4, 2008, Pages 575-587

  Nimmagadda, Sridhar ^a   Shields, Anthony F ^b,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA synthesis; FAU; FBAU; FMAU; Proliferation; Thymidine; Thymidine kinase; Thymidine phosphorylase; Thymidylate synthase

Indexed keywords

1 (2' DEOXY 2' FLUORO 1 BETA DARABINOFURANOSYL) 5 BROMOURACIL BR 76; 1 (2' DEOXY 2' FLUORO 1 BETA DARABINOFURANOSYL) 5 BROMOURACIL F 18; 1 (2' DEOXY 2' FLUORO 1 BETA DEXTRO ARABINOFURANOSYL) METHYLURACIL C 11; 1 (2' DEOXY 2' FLUORO 1 BETA DEXTRO ARABINOFURANOSYL) METHYLURACIL F 18; 1 (2' DEOXY 2' FLUORO BETA DEXTRO ARABINOFURANOSYL) URACIL C 14; 1 (2' DEOXY 2' FLUORO BETA DEXTRO ARABINOFURANOSYL) URACIL F 18; 3' DEOXY 3' FLUORODEOXYTHYMIDINE F 18; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5' DEOXY 5' FLUOROTHYMIDINE F 18; AURORA KINASE INHIBITOR; BROMINE 76; BROXURIDINE; CANERTINIB; CAPECITABINE F 18; CARBON 11; CCT 129202; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; IDOXURIDINE; METHOTREXATE; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; THYMIDINE C 11; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; DNA REPLICATION; DNA STRUCTURE; DNA SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVATION; HODGKIN DISEASE; HUMAN; IMAGE QUALITY; IMAGING; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DNA REPLICATION; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 52549092163     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9148-5     Document Type: Review

References (125)

1. P. Laverman O. C. Boerman F. H. Corstens W. J. Oyen 2002 Fluorinated amino acids for tumour imaging with positron emission tomography European Journal of Nuclear Medicine and Molecular Imaging 29 681 690
2. M. Yoshimoto A. Waki A. Obata T. Furukawa Y. Yonekura Y. Fujibayashi 2004 Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate Nuclear Medicine and Biology 31 859 865
3. D. A. Mankoff A. F. Shields K. A. Krohn 2005 PET imaging of cellular proliferation Radiologic Clinics of North America 43 153 167
4. L. M. Kenny E. O. Aboagye P. M. Price 2004 Positron emission tomography imaging of cell proliferation in oncology Clinical Oncology (Royal College of Radiologists (Great Britain)) 16 176 185
5. 11C-methyl) thymidine Proceedings of the National Academy of Sciences of the United States of America 69 988 992
6. A. F. Shields D. V. Coonrod R. C. Quackenbush J. J. Crowley 1987 Cellular sources of thymidine nucleotides: Studies for PET Journal of Nuclear Medicine 28 1435 1440
7. R. C. Quackenbush A. F. Shields 1988 Local Re-utilization of thymidine in normal mouse tissues as measured with iododeoxyuridine Cell and Tissue Kinetics 21 381 387
8. A. F. Shields K. Lim J. Grierson J. Link K. A. Krohn 1990 Utilization of labeled thymidine in DNA synthesis: studies for PET Journal of Nuclear Medicine 31 337 342
9. R. Adler B. R. McAuslan 1974 Expression of thymidine kinase variants is a function of the replicative state of cells Cell 2 113 117
10. L. J. Bello 1974 Regulation of thymidine kinase synthesis in human cells Experimental Cell Research 89 263 274
11. L. F. Johnson L. G. Rao A. J. Muench 1982 Regulation of thymidine kinase enzyme level in serum-stimulated mouse 3T6 fibroblasts Experimental Cell Research 138 79 85
12. J. L. Sherley T. J. Kelly 1988 Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells Journal of Biological Chemistry 263 375 382
13. P. Broet S. Romain A. Daver G. Ricolleau V. Quillien A. Rallet 2001 Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients Journal of Clinical Oncology 19 2778 2787
14. M. Hallek L. Wanders S. Strohmeyer B. Emmerich 1992 Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications Annals of Hematology 65 1 5
15. S. Svobodova O. Topolcan L. Holubec V. Treska A. Sutnar K. Rupert 2007 Prognostic importance of thymidine kinase in colorectal and breast cancer Anticancer Research 27 1907 1909
16. S. Romain I. J. Christensen O. Chinot I. Balslev C. Rose P. -M. Martin 1995 Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer International Journal of Cancer 61 7 12
17. Q. P. Dou S. Zhao A. H. Levin J. Wang K. Helin A. B. Pardee 1994 G1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter Journal of Biological Chemistry 269 1306 1313
18. 18F-]FLT and positron emission tomography Nature Medicine 4 1334 1336
19. C. W. Carreras D. V. Santi 1995 The catalytic mechanism and structure of thymidylate synthase Annual Reviews of Biochemical 64 721 762
20. G. J. Peters H. H. Backus S. Freemantle B. van Triest G. Codacci-Pisanelli C. L. van der Wilt 2002 Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism Biochimica et Biophysica Acta 1587 194 205
21. B. van Triest H. M. Pinedo Y. van Hensbergen K. Smid F. Telleman P. S. Schoenmakers 1999 Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines Clinical Cancer Research 5 643 654
22. B. C. Pestalozzi H. F. Peterson R. D. Gelber A. Goldhirsch B. A. Gusterson H. Trihia 1997 Prognostic importance of thymidylate synthase expression in early breast cancer Journal of Clinical Oncology 15 1923 1931
23. P. G. Johnston H. J. Lenz C. G. Leichman K. D. Danenberg C. J. Allegra P. V. Danenberg 1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Research 55 1407 1412
24. M. Friedkin D. Roberts 1954 The enzymatic synthesis of nucleosides. II. Thymidine and related pyrimidine nucleosides Journal of Biological Chemistry 207 257 266
25. M. Friedkin D. Roberts 1954 The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue Journal of Biological Chemistry 207 245 256
26. M. H. Iltzsch M. H. el Kouni S. Cha 1985 Kinetic studies of thymidine phosphorylase from mouse liver Biochemistry 24 6799 6807
27. T. Sumizawa T. Furukawa M. Haraguchi A. Yoshimura A. Takeyasu M. Ishizawa 1993 Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor Journal of Biochemistry (Tokyo) 114 9 14
28. K. Usuki J. Saras J. Waltenberger K. Miyazono G. Pierce A. Thomason 1992 Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity Biochemical and Biophysical Research Communications 184 1311 1316
29. M. Toi M. A. Rahman H. Bando L. W. C. Chow 2005 Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment The Lancet Oncology 6 158 166
30. R. W. Klecker Jr. J. M. Collins 2001 Thymidine phosphorylase as a target for imaging and therapy with thymine analogs Cancer Chemotherapy and Pharmacology 48 407 412
31. A. Dimitrakopoulou L. G. Strauss J. H. Clorius H. Ostertag P. Schlag M. Heim 1993 Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma Journal of Nuclear Medicine 34 1075 1081
32. A. Dimitrakopoulou-Strauss L. G. Strauss P. Schlag P. Hohenberger M. Mohler F. Oberdorfer 1998 Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma Journal of Nuclear Medicine 39 1197 1202
33. A. F. Shields M. M. Graham S. M. Kozawa L. B. Kozell J. M. Link E. R. Swenson 1992 Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds Journal of Nuclear Medicine 33 581 584
34. D. A. Mankoff A. F. Shields M. M. Graham J. M. Link K. A. Krohn 1996 A graphical analysis method for estimating blood-to-tissue transfer constants for tracers with labeled metabolites Journal of Nuclear Medicine 37 2049 2057
35. A. F. Shields D. Mankoff M. M. Graham M. Zheng S. M. Kozawa J. Link 1996 Analysis of [2-11C]thymidine blood metabolites for imaging with PET Journal of Nuclear Medicine 37 290 296
36. D. A. Mankoff A. F. Shields M. M. Graham J. M. Link J. F. Eary K. A. Krohn 1998 Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis Journal of Nuclear Medicine 39 1043 1055
37. A. Russo L. Gianni T. J. Kinsella R. W. Klecker Jr. J. Jenkins J. Rowland 1984 Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors Cancer Research 44 1702 1705
38. M. Bergstrom L. Lu K. J. Fasth F. Wu E. Bergstrom-Pettermann V. Tolmachev 1998 In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker Journal of Nuclear Medicine 39 1273 1279
39. O. Gudjonssona M. Bergstrom S. Kristjansson F. Wu G. Nyberg K. J. Fasth 2001 Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker Nuclear Medicine and Biology 28 59 65
40. J. Tjuvajev A. Muraki J. Ginos J. Berk J. Koutcher D. Ballon 1993 Iododeoxyuridine uptake and retention as a measure of tumor growth Journal of Nuclear Medicine 34 1152 1162
41. J. G. Tjuvajev H. A. Macapinilac F. Daghighian A. M. Scott J. Z. Ginos R. D. Finn 1994 Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine Journal of Nuclear Medicine 35 1407 1417
42. R. G. Blasberg U. Roelcke R. Weinreich B. Beattie K. von Ammon Y. Yonekawa 2000 Imaging brain tumor proliferative activity with [124I]iododeoxyuridine Cancer Research 60 624 635
43. J. S. Rasey J. R. Grierson L. W. Wiens P. D. Kolb J. L. Schwartz 2002 Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells Journal of Nuclear Medicine 43 1210 1217
44. J. Toyohara A. Waki S. Takamatsu Y. Yonekura Y. Magata Y. Fujibayashi 2002 Basis of FLT as a cell proliferation marker: Comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines Nuclear Medicine and Biology 29 281 287
45. J. L. Schwartz Y. Tamura R. Jordan J. R. Grierson K. A. Krohn 2004 Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy-3′fluorothymidine uptake Nuclear Medicine and Biology 31 419 423
46. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo Cancer Research 65 4202 4210
47. N. Oyama D. E. Ponde C. Dence J. Kim Y. C. Tai M. J. Welch 2004 Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation Journal of Nuclear Medicine 45 519 525
48. C. J. Sherr J. M. Roberts 1995 Inhibitors of mammalian G1 cyclin-dependent kinases Genes & Development 9 1149 1163
49. H. Rotheneder S. Geymayer E. Haidweger 1999 Transcription factors of the Sp1 family: Interaction with E2F and regulation of the murine thymidine kinase promoter Journal of Molecular Biology 293 1005 1015
50. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice Journal of Nuclear Medicine 45 1754 1758
51. 3H-fluorothymidine using preclinical tumor models Clinical Cancer Research 12 4590 4597
52. 18F-]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors European Journal of Nuclear Medicine and Molecular Imaging 33 412 419
53. J. E. Bolden M. J. Peart R. W. Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nature Reviews. Drug Discovery 5 769 784
54. L. Catley E. Weisberg Y. T. Tai P. Atadja S. Remiszewski T. Hideshima 2003 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 2615 2622
55. 18F-] fluorothymidine positron emission tomography Cancer Research 66 7621 7629
56. M. A. Olayioye R. M. Neve H. A. Lane N. E. Hynes 2000 The ErbB signaling network: receptor heterodimerization in development and cancer EMBO Journal 19 3159 3167
57. P. A. Janne J. von Pawel R. B. Cohen L. Crino C. A. Butts S. S. Olson 2007 Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer Journal of Clinical Oncology 25 3936 3944
58. R. G. Zinner J. Nemunaitis I. Eiseman H. J. Shin S. C. Olson J. Christensen 2007 Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer Clinical Cancer Research 13 3006 3014
59. D. S. Dorow C. Cullinane N. Conus P. Roselt D. Binns T. J. McCarthy 2006 Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033 European Journal of Nuclear Medicine and Molecular Imaging 33 441 452
60. R. D. Carvajal A. Tse G. K. Schwartz 2006 Aurora kinases: New targets for cancer therapy Clinical Cancer Research 12 6869 6875
61. F. Chan C. Sun M. Perumal Q. D. Nguyen V. Bavetsias E. McDonald 2007 Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity Molecular Cancer Therapeutics 6 3147 3157
62. 18F-]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography Cancer Research 63 3791 3798
63. 18F-] fluorothymidine uptake and retention in dogs Molecular Imaging Biology 4 1 83 89
64. M. Muzi D. A. Mankoff J. R. Grierson J. M. Wells H. Vesselle K. A. Krohn 2005 Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies Journal of Nuclear Medicine 46 371 380
65. 18F- 3'-fluorothymidine metabolism and retention European Journal of Nuclear Medicine and Molecular Imaging 32 1269 1275
66. B. Munch-Petersen L. Cloos G. Tyrsted S. Eriksson 1991 Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides Journal of Biological Chemistry 266 9032 9038
67. 18F-FLT): A pilot study European Journal of Surgical Oncology 32 39 43
68. 18F-]FLT PET for diagnosis and staging of thoracic tumours European Journal of Nuclear Medicine and Molecular Imaging 30 1407 1412
69. 18F-]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods Cancer Research 65 10104 10112
70. 18F-FDG Journal of Nuclear Medicine 44 1426 1431
71. 18F-FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors Clinical Cancer Research 8 3315 3323
72. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer European Journal of Nuclear Medicine and Molecular Imaging 34 10 1610 1616
73. Jeraj, R., McCall, K., Simoncic, U., & Nickles, J. (2007). Monitoring of radiation effects with FLT-PET imaging. In Joint Molecular Imaging Conference, Society of Molecular Imaging and Academy of Molecular Imaging: Providence, RI.
74. McArthur, G., Hicks, R., Binns, D., Shalinsky, D., McCarthy, T., Anderes, K., et al. (2007). Positron-emission tomography reveals early flare in uptake of FLT in tumors following chemotherapy with gemcitabine. [abstract]. In Joint Molecular Imaging Conference, Society of Molecular Imaging and Academy of Molecular Imaging: Providence, RI.
75. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients Journal of Nuclear Medicine 48 726 735
76. 18F-FDG PET in esophageal cancer Journal of Nuclear Medicine 46 400 404
77. 18F-fluorothymidine for imaging of primary breast cancer: A pilot study European Journal of Nuclear Medicine and Molecular Imaging 31 720 724
78. 18F]fluorothymidine positron emission tomography European Journal of Nuclear Medicine and Molecular Imaging 34 9 1339 1347
79. 18F-]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Molecular Imaging and Biology 8 36 42
80. A. K. Buck M. Bommer S. Stilgenbauer M. Juweid G. Glatting H. Schirrmeister 2006 Molecular imaging of proliferation in malignant lymphoma Cancer Research 66 11055 11061
81. 18F-]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease Cancer Research 63 2681 2687
82. 18F-] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma Clinical Cancer Research 13 3552 3558
83. B. Kasper G. Egerer M. Gronkowski S. Haufe T. Lehnert M. Eisenhut 2007 Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG-and FLT-PET Leukemia & Lymphoma 48 746 753
84. 11C-]methyl-l-methionine for therapy monitoring in patients with rectal cancer European Journal of Nuclear Medicine and Molecular Imaging 29 789 796
85. 18F- fluorothymidine in patients with gliomas Journal of Nuclear Medicine 47 1612 1621
86. 18F-FLT PET: Comparison with 18F-FDG Journal of Nuclear Medicine 46 945 952
87. 18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors European Journal of Nuclear Medicine and Molecular Imaging 32 653 659
88. T. Saga H. Kawashima N. Araki J. A. Takahashi Y. Nakashima T. Higashi 2006 Evaluation of primary brain tumors with FLT-PET: Usefulness and limitations Clinical Nuclear Medicine 31 774 780
89. 18F-]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: Comparison with Gd-DTPA enhanced magnetic resonance imaging Molecular Imaging and Biology 8 340 347
90. 18-fluorothymidine kinetics of malignant brain tumors European Journal of Nuclear Medicine and Molecular Imaging 34 1003 1011
91. J. R. Bading A. H. Shahinian A. Vail P. Bathija G. W. Koszalka R. T. Koda 2004 Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-beta- d-arabinofuranosyluracil (FMAU) in tumor-bearing rats Nuclear Medicine and Biology 31 407 418
92. M. Ebuchi S. Sakamoto H. Kudo J. Nagase M. Endo 1995 Clinicopathological stages and pyrimidine nucleotide synthesis in human mammary carcinomas Anticancer Research 15 1481 1484
93. 18F-FMAU and PET Journal of Nuclear Medicine 46 292 296
94. 18F-FMAU and positron emission tomography in patients with cancer European Journal of Nuclear Medicine and Molecular Imaging 32 15 22
95. J. M. Collins R. W. Klecker A. G. Katki 1999 Suicide prodrugs activated by thymidylate synthase: Rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues Clinical Cancer Research 5 1976 1981
96. C. H. Kao A. Waki M. B. Sassaman E. M. Jagoda L. P. Szajek L. Ravasi 2002 Evaluation of [76Br]FBAU 3′,5′-dibenzoate as a lipophilic prodrug for brain imaging Nuclear Medicine and Biology 29 527 535
97. L. Lu M. Bergstrom K. J. Fasth B. Langstrom 2000 Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats Journal of Nuclear Medicine 41 1746 1752
98. I. Borbath V. Gregoire M. Bergstrom D. Laryea B. Langstrom S. Pauwels 2002 Use of 5-[(76)Br]bromo-2′-fluoro-2′-deoxyuridine as a ligand for tumour proliferation: Validation in an animal tumour model European Journal of Nuclear Medicine and Molecular Imaging 29 19 27
99. T. Xing F. Wu O. Brodin K. J. Fasth B. Langstrom M. Bergstrom 2000 In vitro PET evaluations in lung cancer cell lines Anticancer Research 20 1375 1380
100. 18F-FLT, and 76Br-BFU as proliferation markers Journal of Nuclear Medicine 43 1688 1698
101. 18F-Fluoro-1-beta-d-arabinofuranosyl)-5- bromouracil: PET imaging studies in dogs Journal of Nuclear Medicine 46 1916 1922
102. Tehrani, O. S., Douglas, K. A., Lawhorn-Crews, J. M., & Shields, A. F. (2008). Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. European Journal of Nuclear Medicine and Molecular Imaging, In press (Feb 12).
103. A. L. Jackman G. A. Taylor A. H. Calvert K. R. Harrap 1984 Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717 Biochemical Pharmacology 33 3269 3275
104. A. L. Jackman G. A. Taylor W. Gibson R. Kimbell M. Brown A. H. Calvert 1991 ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study Cancer Research 51 5579 5586
105. G. A. Taylor A. L. Jackman A. H. Calvert K. R. Harrap 1984 Plasma nucleoside and base levels following treatment with the new thymidylate synthetase inhibitor CB 3717 Advances in Experimental Medicine and Biology 165 Pt B 379 382
106. M. Perumal R. G. Pillai H. Barthel J. Leyton J. R. Latigo M. Forster 2006 Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography Cancer Research 66 8558 8564
107. Y. C. Hu R. A. Komorowski S. Graewin G. Hostetter O. P. Kallioniemi H. A. Pitt 2003 Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer Clinical Cancer Research 9 4165 4171
108. B. Van Triest G. J. Peters 1999 Thymidylate synthase: A target for combination therapy and determinant of chemotherapeutic response in colorectal cancer Oncology 57 179 194
109. C. Aschele S. Lonardi S. Monfardini 2002 Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer Cancer Treatment Reviews 28 27 47
110. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma Cancer Research 57 3415 3423
111. R. W. Klecker A. G. Katki J. M. Collins 1994 Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2′-fluoro-2′-deoxy-beta-d-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells Molecular Pharmacology 46 1204 1209
112. H. Wang P. Oliver L. Nan S. Wang Z. Wang J. K. Rhie 2002 Radiolabeled 2′-fluorodeoxyuracil-beta-d-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-d-arabinofuranoside (FMAU) as tumor-imaging agents in mice Cancer Chemotherapy and Pharmacology 49 419 424
113. 18F-]FAU in patients with tumors: PET studies Cancer Chemotherapy and Pharmacology 57 343 348
114. 18F]FAU [1-(2′-deoxy-2′-fluoro-beta-d-arabinofuranosyl) uracil] in dogs Nuclear Medicine and Biology 30 25 30
115. J. L. Eiseman C. Brown-Proctor P. E. Kinahan J. M. Collins L. W. Anderson E. Joseph 2004 Distribution of 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: Rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase Clinical Cancer Research 10 6669 6676
116. 18F-] fluorothymidine as a tracer of intracellular thymidine phosphorylase activity Nuclear Medicine and Biology 34 471 478
117. 18F-]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers Nuclear Medicine and Biology 31 1033 1041
118. D. Edler B. Glimelius M. Hallstrom A. Jakobsen P. G. Johnston I. Magnusson 2002 Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy Journal of Clinical Oncology 20 1721 1728
119. Y. Liang M. Diehn N. Watson A. W. Bollen K. D. Aldape M. K. Nicholas 2005 Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme Proceedings of the National Academy of Sciences of the United States of America 102 5814 5819
120. T. Sorlie C. M. Perou R. Tibshirani T. Aas S. Geisler H. Johnsen 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proceedings of the National Academy of Sciences of the United States of America 98 10869 10874
121. S. K. Lau P. C. Boutros M. Pintilie F. H. Blackhall C. Q. Zhu D. Strumpf 2007 Three-gene prognostic classifier for early-stage non small-cell lung cancer Journal of Clinical Oncology 25 5562 5569
122. Y. Lu W. Lemon P. Y. Liu Y. Yi C. Morrison P. Yang 2006 A gene expression signature predicts survival of patients with stage I non-small cell lung cancer PLoS Medicine 3 e467
123. D. R. Rhodes J. Yu K. Shanker N. Deshpande R. Varambally D. Ghosh 2004 Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression Proceedings of the National Academy of Sciences of the United States of America 101 9309 9314
124. C. M. Perou S. S. Jeffrey M. van de Rijn C. A. Rees M. B. Eisen D. T. Ross 1999 Distinctive gene expression patterns in human mammary epithelial cells and breast cancers Proceedings of the National Academy of Sciences of the United States of America 96 9212 9217
125. M. L. Whitfield G. Sherlock A. J. Saldanha J. I. Murray C. A. Ball K. E. Alexander 2002 Identification of genes periodically expressed in the human cell cycle and their expression in tumors Molecular Biology of the Cell 13 1977 2000